Investigational drug · Phase 3
MK-1084
Also called: Calderasib
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Colon Adenocarcinoma, Rectal Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
18
Any phase or sponsor naming "MK-1084"
First trial start
2024
May 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-1084", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Colon Adenocarcinoma
- Rectal Adenocarcinoma
- Lung Neoplasm Malignant
- Neoplasm Malignant
- Malignant Neoplasm
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-1084" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05067283 · 830 participants (planned) · Start Dec 17, 2021 · Primary completion Feb 25, 2030
Drug: Calderasib; Pembrolizumab and 6 more · For: Advanced Solid Tumors
Sites: Tampa, Florida; Grand Rapids, Michigan; Hackensack, New Jersey · 75 sites in all
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07190248 · 675 participants (planned) · Start Oct 8, 2025 · Primary completion Dec 7, 2029
Drug: Calderasib; Pembrolizumab (+) Berahyaluronidase alfa and 3 more · For: Non-small Cell Lung Cancer
Sites: Birmingham, Alabama; Beverly Hills, California; Farmington, Connecticut · 226 sites in all
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06997497 · 477 participants (planned) · Start Jul 16, 2025 · Primary completion Mar 28, 2029
Drug: Calderasib; Oxaliplatin and 5 more · For: Colon Adenocarcinoma; Rectal Adenocarcinoma
Sites: Phoenix, Arizona; Fountain Valley, California; Los Angeles, California · 247 sites in all
- MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07431827 · 400 participants (planned) · Start Mar 18, 2026 · Primary completion Oct 26, 2039
Drug: Calderasib; MK-3475A and 1 more · For: Non-small Cell Lung Cancer
Sites: Ciudad Autónoma de Buenos Aires, Argentina; Rosario, Argentina; CABA, Argentina · 125 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06345729 · 348 participants (planned) · Start May 24, 2024 · Primary completion Jan 24, 2028
Drug: Calderasib; Pembrolizumab · For: Non-small Cell Lung Cancer
Sites: Bakersfield, California; Beverly Hills, California; Stamford, Connecticut · 248 sites in all
- A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07554339 · 310 participants (planned) · Start Jun 18, 2026 · Primary completion Dec 15, 2032
Drug: Calderasib; Durvalumab · For: Non-small Cell Lung Cancer
Sites: Atlanta, Georgia; Savannah, Georgia; Lisle, Illinois · 119 sites in all
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07209111 · 150 participants (planned) · Start Dec 4, 2025 · Primary completion Apr 9, 2032
Drug: Calderasib; Cetuximab · For: Neoplasm Malignant
Sites: Baltimore, Maryland; Grand Rapids, Michigan; Las Vegas, Nevada · 72 sites in all
- KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07252739 · 140 participants (planned) · Start Dec 19, 2025 · Primary completion Nov 15, 2029
Drug: MK-1084; Pembrolizumab and 3 more · For: Malignant Neoplasm
Sites: Clermont, Florida; Fargo, North Dakota; Sioux Falls, South Dakota · 40 sites in all
- A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07286149 · 140 participants (planned) · Start Apr 30, 2026 · Primary completion Aug 17, 2029
Drug: MK-1084; Patritumab deruxtecan and 3 more · For: Lung Neoplasm Malignant
Sites: Clermont, Florida; Chicago, Illinois; Portland, Oregon · 29 sites in all
- Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)Active, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05853367 · 95 participants · Start Jul 6, 2023 · Primary completion Jun 24, 2028
Drug: MK-0472; Pembrolizumab and 1 more · For: Metastatic Solid Tumors; Advanced Solid Tumors
Sites: Chicago, Illinois; Louisville, Kentucky; Hackensack, New Jersey · 25 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Theoretical study of KRAS G12C secondary mutations influencing inhibitor resistance.
Karim RM, Kawaguchi K, Nagao H · Biophys Physicobiol 2026
- A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science.
Boby JM, Ilerhunmwuwa N, Benny JM, et al. · Cancer Invest 2026
- From KRASG12D to Pan-KRAS InhibitorsৄA Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.
Ma X, Sloman DL, Henderson TJ, et al. · J Med Chem 2026
- Direct Amidation of Tertiary N-Benzylamines.
MacAllister CA, Jiang Y, Sather AC · Org Lett 2026
- Asymmetric Synthesis of KRAS G12C Inhibitor MK-1084 via a Crystallization-Induced Diastereomer Transformation (CIDT).
Li H, Shang G, Song ZJ, et al. · Org Lett 2026
- Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor.
Ma X, Sloman DL, Duggal R, et al. · J Med Chem 2024
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.